Stem Cell Transplantation

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Angeles TherapeuticsCA - Los Angeles

2 programs

Cyclophosphamide Dose Level 1Phase 21 trial

Bright Ideas Problem-Solving Skills TrainingN/A1 trial

Active Trials

NCT07219524Completed38Est. May 2023

NCT02512679Terminated20Est. Feb 2014

SanofiPARIS, France

1 program

PlerixaforPHASE_1_21 trial

Active Trials

NCT00822770Completed47Est. Oct 2012

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Angeles TherapeuticsCyclophosphamide Dose Level 1

SanofiPlerixafor

Angeles TherapeuticsBright Ideas Problem-Solving Skills Training

Clinical Trials (3)

Total enrollment: 105 patients across 3 trials

NCT02512679 Angeles TherapeuticsCyclophosphamide Dose Level 1

Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells

Start: Feb 2007Est. completion: Feb 201420 patients

Phase 2Terminated

NCT00822770 SanofiPlerixafor

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Start: Jan 2009Est. completion: Oct 201247 patients

Phase 1/2Completed

NCT07219524 Angeles TherapeuticsBright Ideas Problem-Solving Skills Training

Problem-Solving Skills Training for Parents of Children Undergoing Hematopoietic Stem Cell Transplantation: A Feasibility Study

Start: Nov 2020Est. completion: May 202338 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.